HAS Provides Conditional Reimbursement for Pirtobrutinib and Restricted Use for Upadacitinib | iPharmaCenter
HAS Issues Conditional Reimbursement for JAYPIRCA (Pirtobrutinib) in Relapsed or Refractory Mantle Cell Lymphoma The French Health Authority (HAS) delivered a favorable opinion for reimbursement of JAYPIRCA (pirtobrutinib) only when used as monotherapy for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received a Bruton's tyrosine kinase (BTK) inhibitor and are ineligible for treatment with TECARTUS (brexucabtagene autoleucel). In ot
PBS Adds Zytorvi, First Funded Immunotherapy Option for Australians with Recurrent or Metastatic Nasopharyngeal Carcinoma | iPharmaCenter
Zytorvi PBS listing Toripalimab‑based immunotherapy has been added to Australia’s Pharmaceutical Benefits Scheme (PBS) as the first funded immune checkpoint inhibitor for eligible people with nasopharyngeal carcinoma whose disease has recurred or spread. From 1 December 2025, Zytorvi (toripalimab), a next‑generation PD‑1 inhibitor supplied by Dr. Reddy’s Laboratories under licence from Shanghai Junshi Biosciences, will be reimbursed on the PBS for defined adult nasopharynge
FDA Clears Breyanzi as the First CAR T‑Cell Therapy for Relapsed or Refractory Marginal Zone Lymphoma in the US | iPharmaCenter
FDA Greenlights Breyanzi: Pioneering CAR T-Cell Therapy for Marginal Zone Lymphoma The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel) for adults battling relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of systemic therapy. This groundbreaking decision positions Breyanzi as the first CAR T-cell therapy approved in the U.S. for this challenging rare B-cell malignancy, offering new hope to patients with limit
Johnson & Johnson Secures European Commission Approval for IMAAVY (Nipocalimab) to Treat Generalised Myasthenia Gravis
The European Commission has granted Marketing Authorisation to Johnson & Johnson for IMAAVY (nipocalimab), a novel FcRn-blocking antibody therapy designed to help people living with generalised myasthenia gravis (gMG). The approval covers both adult and adolescent patients aged 12 years and older who test positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibodies. gMG is a chronic autoimmune neuromuscular disorder that impairs communicati
Sun Pharma Launches ILUMYA in India for Psoriasis Patients | iPharmaCenter
Sun Pharma Launches ILUMYA in India Sun Pharma has unveiled its globally recognized innovative medication, ILUMYA (Tildrakizumab), now available in India for managing moderate-to-severe plaque psoriasis. This advanced biologic therapy has garnered extensive acceptance among dermatologists in the United States and internationally as a reliable and safe option for treating this condition. Also read: Top pharmaceutical companies by revenues in 2025 Long-Term Efficacy of ILUMYA
US FDA Accepts AstraZeneca’s Baxdrostat for Priority Review in Resistant Hypertension
The U.S. Food and Drug Administration (FDA) has accepted AstraZeneca’s New Drug Application (NDA) for baxdrostat under Priority Review , marking a key regulatory milestone for patients with hard‑to‑control or treatment‑resistant hypertension. The application seeks approval for baxdrostat as an add‑on therapy to existing antihypertensive treatments in adult patients whose blood pressure remains inadequately controlled despite standard care. Also read: Top 10 pharmaceutical c